Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics, Inc (RNTX)
:RNTX
RNTX Stock Chart & Stats
$1.28
--
Market closed
$1.28
--
Day’s Range― - ―
52-Week Range$1.04 - $4.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)190.32K
Market Cap
$30.14M
Enterprise Value$73.15M
Total Cash (Recent Filing)$5.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 14, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding23,547,428
10 Day Avg. Volume121,556
30 Day Avg. Volume190,316
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-73.15K
Enterprise Value/Ebitda-5.86
Forecast
1Y Price Target
$10.00Price Target Upside681.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressThe FDA confirmed that new GLP rat toxicity studies would not be required.
Stock ValuationThe disconnect between the current $1.21 price and the $10 price target is seen as a positive for the stock.
Bears Say
Cash Flow ConcernsCash of $5.7MM, plus the recent Yorkville Capital transaction, can fund operations only through Q4:2025, raising skepticism about the company's ability to generate the needed funds in a competitive IPF space.
Financial UncertaintyThere is concern about the lack of sufficient funding to restart its Phase 2 trial in the US and the ability to raise the approximately $40MM needed to run the study.
Regulatory DelaysRNTX’s Q2 update was disappointing, as the company is still waiting for a meeting with the FDA regarding the clinical hold of the Phase 2 RENEW trial which is expected to delay the trial by up to 10 months.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics, Inc’s price range in the past 12 months?
Rein Therapeutics, Inc lowest stock price was $1.04 and its highest was $4.40 in the past 12 months.
What is Rein Therapeutics, Inc’s market cap?
Rein Therapeutics, Inc’s market cap is $30.14M.
When is Rein Therapeutics, Inc’s upcoming earnings report date?
Rein Therapeutics, Inc’s upcoming earnings report date is Nov 14, 2025 which is in 24 days.
How were Rein Therapeutics, Inc’s earnings last quarter?
Rein Therapeutics, Inc released its earnings results on Aug 06, 2025. The company reported -$0.282 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.062.
Is Rein Therapeutics, Inc overvalued?
According to Wall Street analysts Rein Therapeutics, Inc’s price is currently Undervalued.
Does Rein Therapeutics, Inc pay dividends?
Rein Therapeutics, Inc does not currently pay dividends.
What is Rein Therapeutics, Inc’s EPS estimate?
Rein Therapeutics, Inc’s EPS estimate is -0.24.
How many shares outstanding does Rein Therapeutics, Inc have?
Rein Therapeutics, Inc has 23,547,428 shares outstanding.
What happened to Rein Therapeutics, Inc’s price movement after its last earnings report?
Rein Therapeutics, Inc reported an EPS of -$0.282 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Rein Therapeutics, Inc?
Currently, no hedge funds are holding shares in RNTX
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.64%
12-Months-Change
Fundamentals
Return on Equity
-79.38%
Trailing 12-Months
Asset Growth
-47.46%
Trailing 12-Months
RNTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(681.25% Upside)
Technical Analysis
Sonnet BioTherapeutics Holdings
―
Kezar Life Sciences
―
Vivos Therapeutics
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
1.95% Insiders
4.46% Mutual Funds
22.38% Other Institutional Investors
67.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---